Department of Nuclear Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Haemophilia. 2014 Jan;20(1):e45-50. doi: 10.1111/hae.12252. Epub 2013 Aug 12.
Despite recent advances including new therapeutic options and availability of primary prophylaxis in haemophiliacs, haemophilic synovitis is still the major clinical problem in significant patient population worldwide. We retrospectively reviewed our 10-year experience with Y-90 radiosynovectomy to determine the outcome in the knee joints of patients with haemophilic synovitis. Between 2002 and 2012, 82 knee joints of 67 patients with haemophilic synovitis were treated with Y-90 radiosynovectomy. The mean age was 16.8 ± 7.8 years (range: 5-39 years). The mean follow-up period was 39.6 ± 25.6 months (range: 12-95 months). Failure of therapy represented re-bleeding after a radiosynovectomy was used as an end point in patient time to progression (TTP) analysis. The median TTP was calculated as 72.0 ± 3.6 months (95% CI 64.8-79.1 months) in Kaplan-Meier analysis. The 1, 3 and 5-year survival rates were 89%, 73% and 63% respectively. Longer TTP (hazard ratio for progression, 2.5; P = 0.00) was evident in patients who have greater reduction in bleeding frequency within 6 months after radiosynovectomy. We did not find a relationship between the TTP and the following variables: age, type and severity of haemophilia, the presence or absence of inhibitor, the radiological score, range of motion status of joints and the pretreatment bleeding frequency. We concluded that Y-90 radiosynovectomy in knee joint represents an important resource for the treatment of haemophilic synovitis, markedly reducing joint bleeding and long-term durability, irrespective of the radiographic stage and inhibitor status.
尽管近年来取得了一些进展,包括新的治疗选择和血友病患者的初级预防措施,但在全球范围内,血友病性滑膜炎仍然是许多患者的主要临床问题。我们回顾性地分析了我们使用 Y-90 放射性滑膜切除术治疗血友病性滑膜炎的 10 年经验,以确定该方法治疗膝关节的效果。2002 年至 2012 年间,我们对 67 例血友病性滑膜炎患者的 82 个膝关节进行了 Y-90 放射性滑膜切除术治疗。患者的平均年龄为 16.8 ± 7.8 岁(5-39 岁)。平均随访时间为 39.6 ± 25.6 个月(12-95 个月)。以放射滑膜切除术后再次出血作为进展终点,采用患者无进展时间(TTP)分析评估治疗失败。Kaplan-Meier 分析显示,中位 TTP 为 72.0 ± 3.6 个月(95%CI:64.8-79.1 个月)。1、3、5 年生存率分别为 89%、73%和 63%。放射滑膜切除术后 6 个月内出血频率降低程度更大的患者 TTP 更长(进展风险比,2.5;P = 0.00)。我们未发现 TTP 与以下变量之间存在相关性:年龄、血友病的类型和严重程度、抑制剂的存在与否、影像学评分、关节活动度和治疗前出血频率。我们得出结论,Y-90 放射性滑膜切除术是治疗血友病性滑膜炎的重要手段,可显著减少关节出血和长期耐久性,无论影像学分期和抑制剂状态如何。